Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week High – What’s Next?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) hit a new 52-week high during trading on Monday . The company traded as high as $18.47 and last traded at $18.3310, with a volume of 97753 shares trading hands. The stock had previously closed at $18.15.

Analyst Upgrades and Downgrades

Several research firms have commented on TRVI. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Monday, April 20th. Oppenheimer reaffirmed an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, March 9th. Stifel Nicolaus set a $30.00 target price on shares of Trevi Therapeutics in a research report on Friday, May 8th. HC Wainwright reiterated a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. Finally, JonesTrading lowered their price target on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, March 19th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $22.67.

Trevi Therapeutics Trading Up 0.1%

The stock has a 50 day simple moving average of $14.88 and a 200 day simple moving average of $12.84. The firm has a market capitalization of $2.65 billion, a PE ratio of -58.28 and a beta of 1.04.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). As a group, equities analysts anticipate that Trevi Therapeutics, Inc. will post -0.47 earnings per share for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its position in shares of Trevi Therapeutics by 194.5% in the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after acquiring an additional 2,996 shares during the period. KBC Group NV purchased a new stake in shares of Trevi Therapeutics during the first quarter worth about $29,000. Hilton Head Capital Partners LLC bought a new stake in shares of Trevi Therapeutics in the fourth quarter worth about $40,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Trevi Therapeutics in the fourth quarter worth about $50,000. Finally, Strs Ohio purchased a new position in Trevi Therapeutics during the 1st quarter valued at about $52,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.